Telviran® es Zovirax® 800 mg acyclovir hatoanyagtartalmu tablettak osszehasonlito farmakokinetikaja egeszseges onkenteseken

Translated title of the contribution: Comparative pharmacokinetic study of 800 mg acyclovir-containing Telviran® and Zovirax® tablets in healthy volunteers

Baloghné Nemes Katalin, Grézal Gyula, Dalmadiné Kiss Borbála, Tömlo Judit, Patai Valentina, Nagy Lajos, G. Mózsik, Csörgo Margit, Szentpéteri Imre, I. Klebovich

Research output: Contribution to journalArticle

Abstract

The authors performed a detailed comparative clinical and pharmacokinetic study with two 800 mg acyclovir containing tablets, namely the Telviran® (EGIS Pharmaceuticals Ltd.) and the Zovirax® (Wellcome Foundation Ltd.). The determination of the detailed pharmacokinetic parameters and the relative bioavailability was carried out on 24 healthy male volunteers in a two way, open, randomised, cross-over design study after single dose administration. The plasma concentration of acyclovir was determined by a newly developed and validated highly sensitive (LLOQ = 10 ng/ml) HPLC-UV bioanalytical method, after sample preparation with RP-18 solid phase extraction method (SPE). The individual pharmacokinetic parameters calculated from the time-plasma concentration curve (t(max), C(max), AUC(0-∞), AUC0-16, AUC(0-t), AUC(0-z), AUC(Rest), t(β)( 1/2 ), MRT, C(max)/AUC(0-∞)) were compared with statistical methods (ANOVA, ANOVA(log), Confidence interval, Schuirmann, Wilcoxon tests). On the basis of the results of the statistical evaluation and the clinical study, there was no significant difference found between the two acyclovir containing preparations. The comparative pharmacokinetic study demonstrated, that the relative bioavailability of the 800 mg Telviran® and Zovirax® tablets are equivalent and the two products are bioequivalent.

Original languageHungarian
Pages (from-to)36-45
Number of pages10
JournalActa Pharmaceutica Hungarica
Volume69
Issue number1
Publication statusPublished - Jan 1999

Fingerprint

Acyclovir
Tablets
Area Under Curve
Healthy Volunteers
Pharmacokinetics
Cross-Over Studies
Biological Availability
Analysis of Variance
Solid Phase Extraction
High Pressure Liquid Chromatography
Confidence Intervals
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Telviran® es Zovirax® 800 mg acyclovir hatoanyagtartalmu tablettak osszehasonlito farmakokinetikaja egeszseges onkenteseken. / Katalin, Baloghné Nemes; Gyula, Grézal; Borbála, Dalmadiné Kiss; Judit, Tömlo; Valentina, Patai; Lajos, Nagy; Mózsik, G.; Margit, Csörgo; Imre, Szentpéteri; Klebovich, I.

In: Acta Pharmaceutica Hungarica, Vol. 69, No. 1, 01.1999, p. 36-45.

Research output: Contribution to journalArticle

Katalin, BN, Gyula, G, Borbála, DK, Judit, T, Valentina, P, Lajos, N, Mózsik, G, Margit, C, Imre, S & Klebovich, I 1999, 'Telviran® es Zovirax® 800 mg acyclovir hatoanyagtartalmu tablettak osszehasonlito farmakokinetikaja egeszseges onkenteseken', Acta Pharmaceutica Hungarica, vol. 69, no. 1, pp. 36-45.
Katalin, Baloghné Nemes ; Gyula, Grézal ; Borbála, Dalmadiné Kiss ; Judit, Tömlo ; Valentina, Patai ; Lajos, Nagy ; Mózsik, G. ; Margit, Csörgo ; Imre, Szentpéteri ; Klebovich, I. / Telviran® es Zovirax® 800 mg acyclovir hatoanyagtartalmu tablettak osszehasonlito farmakokinetikaja egeszseges onkenteseken. In: Acta Pharmaceutica Hungarica. 1999 ; Vol. 69, No. 1. pp. 36-45.
@article{01083071589e41e581c2c399b73f85a2,
title = "Telviran{\circledR} es Zovirax{\circledR} 800 mg acyclovir hatoanyagtartalmu tablettak osszehasonlito farmakokinetikaja egeszseges onkenteseken",
abstract = "The authors performed a detailed comparative clinical and pharmacokinetic study with two 800 mg acyclovir containing tablets, namely the Telviran{\circledR} (EGIS Pharmaceuticals Ltd.) and the Zovirax{\circledR} (Wellcome Foundation Ltd.). The determination of the detailed pharmacokinetic parameters and the relative bioavailability was carried out on 24 healthy male volunteers in a two way, open, randomised, cross-over design study after single dose administration. The plasma concentration of acyclovir was determined by a newly developed and validated highly sensitive (LLOQ = 10 ng/ml) HPLC-UV bioanalytical method, after sample preparation with RP-18 solid phase extraction method (SPE). The individual pharmacokinetic parameters calculated from the time-plasma concentration curve (t(max), C(max), AUC(0-∞), AUC0-16, AUC(0-t), AUC(0-z), AUC(Rest), t(β)( 1/2 ), MRT, C(max)/AUC(0-∞)) were compared with statistical methods (ANOVA, ANOVA(log), Confidence interval, Schuirmann, Wilcoxon tests). On the basis of the results of the statistical evaluation and the clinical study, there was no significant difference found between the two acyclovir containing preparations. The comparative pharmacokinetic study demonstrated, that the relative bioavailability of the 800 mg Telviran{\circledR} and Zovirax{\circledR} tablets are equivalent and the two products are bioequivalent.",
author = "Katalin, {Baloghn{\'e} Nemes} and Gr{\'e}zal Gyula and Borb{\'a}la, {Dalmadin{\'e} Kiss} and T{\"o}mlo Judit and Patai Valentina and Nagy Lajos and G. M{\'o}zsik and Cs{\"o}rgo Margit and Szentp{\'e}teri Imre and I. Klebovich",
year = "1999",
month = "1",
language = "Hungarian",
volume = "69",
pages = "36--45",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "1",

}

TY - JOUR

T1 - Telviran® es Zovirax® 800 mg acyclovir hatoanyagtartalmu tablettak osszehasonlito farmakokinetikaja egeszseges onkenteseken

AU - Katalin, Baloghné Nemes

AU - Gyula, Grézal

AU - Borbála, Dalmadiné Kiss

AU - Judit, Tömlo

AU - Valentina, Patai

AU - Lajos, Nagy

AU - Mózsik, G.

AU - Margit, Csörgo

AU - Imre, Szentpéteri

AU - Klebovich, I.

PY - 1999/1

Y1 - 1999/1

N2 - The authors performed a detailed comparative clinical and pharmacokinetic study with two 800 mg acyclovir containing tablets, namely the Telviran® (EGIS Pharmaceuticals Ltd.) and the Zovirax® (Wellcome Foundation Ltd.). The determination of the detailed pharmacokinetic parameters and the relative bioavailability was carried out on 24 healthy male volunteers in a two way, open, randomised, cross-over design study after single dose administration. The plasma concentration of acyclovir was determined by a newly developed and validated highly sensitive (LLOQ = 10 ng/ml) HPLC-UV bioanalytical method, after sample preparation with RP-18 solid phase extraction method (SPE). The individual pharmacokinetic parameters calculated from the time-plasma concentration curve (t(max), C(max), AUC(0-∞), AUC0-16, AUC(0-t), AUC(0-z), AUC(Rest), t(β)( 1/2 ), MRT, C(max)/AUC(0-∞)) were compared with statistical methods (ANOVA, ANOVA(log), Confidence interval, Schuirmann, Wilcoxon tests). On the basis of the results of the statistical evaluation and the clinical study, there was no significant difference found between the two acyclovir containing preparations. The comparative pharmacokinetic study demonstrated, that the relative bioavailability of the 800 mg Telviran® and Zovirax® tablets are equivalent and the two products are bioequivalent.

AB - The authors performed a detailed comparative clinical and pharmacokinetic study with two 800 mg acyclovir containing tablets, namely the Telviran® (EGIS Pharmaceuticals Ltd.) and the Zovirax® (Wellcome Foundation Ltd.). The determination of the detailed pharmacokinetic parameters and the relative bioavailability was carried out on 24 healthy male volunteers in a two way, open, randomised, cross-over design study after single dose administration. The plasma concentration of acyclovir was determined by a newly developed and validated highly sensitive (LLOQ = 10 ng/ml) HPLC-UV bioanalytical method, after sample preparation with RP-18 solid phase extraction method (SPE). The individual pharmacokinetic parameters calculated from the time-plasma concentration curve (t(max), C(max), AUC(0-∞), AUC0-16, AUC(0-t), AUC(0-z), AUC(Rest), t(β)( 1/2 ), MRT, C(max)/AUC(0-∞)) were compared with statistical methods (ANOVA, ANOVA(log), Confidence interval, Schuirmann, Wilcoxon tests). On the basis of the results of the statistical evaluation and the clinical study, there was no significant difference found between the two acyclovir containing preparations. The comparative pharmacokinetic study demonstrated, that the relative bioavailability of the 800 mg Telviran® and Zovirax® tablets are equivalent and the two products are bioequivalent.

UR - http://www.scopus.com/inward/record.url?scp=14444276080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14444276080&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 36

EP - 45

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 1

ER -